Exit Stage Right: With Prasad Out, Analysts Hope for More Traditional Replacement
As analysts parsed news of Vinay Prasad’s ouster, worries over drug approval delays, cell and gene therapy impacts and more were top of mind.
Hookipa Winds Down, Merck Trims Billions in ‘Reallocation’
Follow along as BioSpace tracks job cuts and restructuring initiatives throughout 2025.
Madrigal Makes Potential $2B+ Bet for CSPC’s GLP-1 Pill
Madrigal will study SYH2086 in combination with Rezdiffra for metabolic dysfunction-associated steatohepatitis, aiming for clinical trials in early 2026.
Sarepta Gets Reprieve, RFK Jr.’s New Changes, Roche’s Alzheimer’s Comeback and Q2 Earnings
Sarepta’s Elevidys is back on the market for ambulatory patients with Duchenne muscular dystrophy, Health Secretary Robert F. Kennedy Jr. reportedly plans to dissolve the U.S. Preventive Services Task Force and “fix” the vaccine injury compensation program, Merck, AstraZeneca and more report Q2 earnings, Novo names a new leader and Roche’s trontinemab impresses at AAIC25.
GSK to Inject ‘Tens of Billions’ in US Amid Trump’s Tariffs, Pipeline Reshuffles
CEO Emma Walmsley maintained that continued investment in the U.S. is a priority for the pharma to ensure its medicines for the country are supplied domestically.
Four Scrappy Biotechs Braving the Stormy Market Alone
Against steep odds and well-established paradigms, these four companies have successfully been commercializing their products on their own.
The Top Five Biopharma Venture Capital Raises of H1, 2025
Though nerves abound for funders and founders in the industry, money continues to flow into startups, sometimes in eye-popping numbers. BioSpace rounds up the biggest raises so far this year.
IRA’s Definition of ‘Drug’ Creates Confusion for Developers
Under the Inflation Reduction Act, medications with the same active ingredient will be treated as the same drug for price negotiation purposes—even if approved by the FDA under a separate application—disincentivizing companies from investing time and money in gaining approval for new formulations and indications.
In the blogs: Read my tips
The well-oiled firm; refundable credits in states; taxing settlement money; and other highlights from our favorite tax bloggers.